258 related articles for article (PubMed ID: 10811986)
1. Expression of TRAIL (Apo2L), DR4 (TRAIL receptor 1), DR5 (TRAIL receptor 2) and TRID (TRAIL receptor 3) genes in multidrug resistant human acute myeloid leukemia cell lines that overexpress MDR 1 (HL60/Tax) or MRP (HL60/AR).
Kim CH; Gupta S
Int J Oncol; 2000 Jun; 16(6):1137-9. PubMed ID: 10811986
[TBL] [Abstract][Full Text] [Related]
2. Molecular determinants of response to TRAIL in killing of normal and cancer cells.
Kim K; Fisher MJ; Xu SQ; el-Deiry WS
Clin Cancer Res; 2000 Feb; 6(2):335-46. PubMed ID: 10690508
[TBL] [Abstract][Full Text] [Related]
3. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha.
Sheikh MS; Burns TF; Huang Y; Wu GS; Amundson S; Brooks KS; Fornace AJ; el-Deiry WS
Cancer Res; 1998 Apr; 58(8):1593-8. PubMed ID: 9563466
[TBL] [Abstract][Full Text] [Related]
4. The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract.
Sheikh MS; Huang Y; Fernandez-Salas EA; El-Deiry WS; Friess H; Amundson S; Yin J; Meltzer SJ; Holbrook NJ; Fornace AJ
Oncogene; 1999 Jul; 18(28):4153-9. PubMed ID: 10435597
[TBL] [Abstract][Full Text] [Related]
5. Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL.
Gómez-Benito M; Martinez-Lorenzo MJ; Anel A; Marzo I; Naval J
Exp Cell Res; 2007 Jul; 313(11):2378-88. PubMed ID: 17462628
[TBL] [Abstract][Full Text] [Related]
6. P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5.
Park SJ; Wu CH; Choi MR; Najafi F; Emami A; Safa AR
Biochem Pharmacol; 2006 Jul; 72(3):293-307. PubMed ID: 16753135
[TBL] [Abstract][Full Text] [Related]
7. An antagonist decoy receptor and a death domain-containing receptor for TRAIL.
Pan G; Ni J; Wei YF; Yu G; Gentz R; Dixit VM
Science; 1997 Aug; 277(5327):815-8. PubMed ID: 9242610
[TBL] [Abstract][Full Text] [Related]
8. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2.
Mérino D; Lalaoui N; Morizot A; Schneider P; Solary E; Micheau O
Mol Cell Biol; 2006 Oct; 26(19):7046-55. PubMed ID: 16980609
[TBL] [Abstract][Full Text] [Related]
9. The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis.
Meng RD; McDonald ER; Sheikh MS; Fornace AJ; El-Deiry WS
Mol Ther; 2000 Feb; 1(2):130-44. PubMed ID: 10933923
[TBL] [Abstract][Full Text] [Related]
10. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in established and primary glioma cell lines.
Jaganathan J; Petit JH; Lazio BE; Singh SK; Chin LS
Neurosurg Focus; 2002 Sep; 13(3):ecp1. PubMed ID: 15844877
[TBL] [Abstract][Full Text] [Related]
11. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
[TBL] [Abstract][Full Text] [Related]
12. Potential mechanisms of resistance to TRAIL/Apo2L-induced apoptosis in human promyelocytic leukemia HL-60 cells during granulocytic differentiation.
Shiiki K; Yoshikawa H; Kinoshita H; Takeda M; Ueno A; Nakajima Y; Tasaka K
Cell Death Differ; 2000 Oct; 7(10):939-46. PubMed ID: 11279540
[TBL] [Abstract][Full Text] [Related]
13. In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-kappa B activity.
Wuchter C; Krappmann D; Cai Z; Ruppert V; Scheidereit C; Dörken B; Ludwig WD; Karawajew L
Leukemia; 2001 Jun; 15(6):921-8. PubMed ID: 11417478
[TBL] [Abstract][Full Text] [Related]
14. Preparation and characterization of a set of monoclonal antibodies to TRAIL and TRAIL receptors DR4, DR5, DcR1, and DcR2.
Liu XS; Zhu Y; Han WN; Li YN; Chen LH; Jia W; Song CJ; Liu F; Yang K; Li Q; Jin BQ
Hybrid Hybridomics; 2003 Apr; 22(2):121-5. PubMed ID: 12831538
[TBL] [Abstract][Full Text] [Related]
15. Control of apoptosis signaling by Apo2 ligand.
Marsters SA; Pitti RA; Sheridan JP; Ashkenazi A
Recent Prog Horm Res; 1999; 54():225-34. PubMed ID: 10548878
[TBL] [Abstract][Full Text] [Related]
16. Sensitization of multidrug resistant human ostesarcoma cells to Apo2 Ligand/TRAIL-induced apoptosis by inhibition of the Akt/PKB kinase.
Cenni V; Maraldi NM; Ruggeri A; Secchiero P; Del Coco R; De Pol A; Cocco L; Marmiroli S
Int J Oncol; 2004 Dec; 25(6):1599-608. PubMed ID: 15547696
[TBL] [Abstract][Full Text] [Related]
17. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors.
Sheridan JP; Marsters SA; Pitti RM; Gurney A; Skubatch M; Baldwin D; Ramakrishnan L; Gray CL; Baker K; Wood WI; Goddard AD; Godowski P; Ashkenazi A
Science; 1997 Aug; 277(5327):818-21. PubMed ID: 9242611
[TBL] [Abstract][Full Text] [Related]
18. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.
Emery JG; McDonnell P; Burke MB; Deen KC; Lyn S; Silverman C; Dul E; Appelbaum ER; Eichman C; DiPrinzio R; Dodds RA; James IE; Rosenberg M; Lee JC; Young PR
J Biol Chem; 1998 Jun; 273(23):14363-7. PubMed ID: 9603945
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy induces death receptor 5 in epithelial ovarian carcinoma.
Arts HJ; de Jong S; Hollema H; ten Hoor K; van der Zee AG; de Vries EG
Gynecol Oncol; 2004 Mar; 92(3):794-800. PubMed ID: 14984943
[TBL] [Abstract][Full Text] [Related]
20. Rel/NF-kappaB transcription factors protect against tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by up-regulating the TRAIL decoy receptor DcR1.
Bernard D; Quatannens B; Vandenbunder B; Abbadie C
J Biol Chem; 2001 Jul; 276(29):27322-8. PubMed ID: 11350953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]